Cytorhodin S derivatives and a process for their preparation

Abstract

Cytorhodin S derivatives, especially cytorhodin S-immunoglobulin complexes are disclosed. Cytorhodin S possesses very high anticancer activity, but the complexes act more selectively on cancer cells and are more useful as an anticancer agent. New intermediate derivatives are also useful as an anticancer agent.

Description

Claims

1. A compound represented by the formula I ##STR34## wherein X is selected from the group consisting of the formulae a) --NH.sub.2 or --NH--(CH.sub.2).sub.2 --SH,

b) ##STR35## wherein R.sup.1 is unsubstituted C.sub.1 -C.sub.5 -alkylene which is substituted with NH.sub.2 or SH, and Y is OH, C.sub.2 H.sub.5 --or the radical NH--(--IgG).sub.1/n, wherein IgG represents an immunoglobulin moiety and n represents an integer of 1-15,

(c) ##STR36## wherein R.sup.2 is lower alkylene, phenylene, C.sub.4 -C.sub.7 -cycloalkylene phenylenyl lower alkyl or C.sub.4 -C.sub.7 -cycloalkylenyl lower alkyl,

d) ##STR37## wherein R.sup.3 is a radical of the formula ##STR38## wherein R.sup.2 is a hereinabove described, and R.sup.4 is lower alkylene, phenylene, C.sub.4 -C.sub.7 -cycloalkylene, phenylenyl lower alkyl or C.sub.4 -C.sub.7 -cycloalkylenyl lower alkyl, wherein IgG represents an immunoglobulin moiety and n represents an integer of 1-15, and

e) ##STR39## wherein IgG represents an immunoglobulin moiety and n represents an integer of 1-15 and a salt thereof.

2. A cytorhodin S derivative as claimed in claim 1, wherein said lower alkylene group is methylene, ethylene or propylene; said phenylene group is p-phenylene or m-phenylene; said C.sub.4 -C.sub.7 cycloalkylene group is cyclohexylene; said phenylenyl lower alkyl group is a phenylenyl-methyl; and said C.sub.4 -C.sub.7 cycloalkenyl lower alkyl group is cyclohexylenyl-methyl.

3. A cytorhodin S derivative according to claim 1, wherein R.sup.1 is a methylene group.

4. A cytorhodin S derivative according to claim 1, wherein said R.sup.1 is a ethylene group.

5. A cytorhodin S derivative according to claim 1, wherein said R.sup.1 is a propylene group.

6. A cytorhodin S derivative according to claim 1, wherein said R.sup.1 is a ethylene group that is substituted with a --NH.sub.2 group.

7. A cytorhodin S derivative according to claim 1, wherein said R.sup.1 is a pentene that is substituted with a --NH.sub.2 group.

8. A compound as defined in claim 1, wherein R.sup.2 is a propylene group and R.sup.4 is a methylene group.

9. A compound as defined in claim 1, wherein n is an integer of 5-12.

10. A compound as defined in claim 1 wherein immunoglobulise moiety the IgG is a moiety of the antibody against carcinoembryonic antigen (CEA).

11. A process for preparing a cytorhodin S derivative of formula (I) as defined in claim 1, wherein X is --NH.sub.2, --NH--(CH.sub.2).sub.2 --SH or --NH--R.sup.1 --CO--Y, wherein R.sup.1 is unsubstituted C.sub.1 -C.sub.5 -alkylene or C.sub.1 -C.sub.5 -alkylene which is substituted with NH.sub.2 or SH, and Y is OH, C.sub.2 H.sub.5 - or the radical NH--(--IgG).sub.1/n wherein IgG represents an immunoglobulin moiety and n represents an integer of 1-15, which comprises the step of reducing a cytorhodin S having the formula (II) ##STR40## with an alkali metal cyanoborohydride in the presence of an ammonium salt or a compound of the formula NH.sub.2 --(CH.sub.2).sub.2 --SH or a compound of the formula ##STR41## where R.sup.1 and Y are as hereinbefore described.

12. The process for preparing a cytorhodin S derivative of the formula (I) as defined in claim 1, wherein X is a group of the formula ##STR42## wherein R.sup.2 is lower alkylene, phenylene, C.sub.4 -C.sub.7 -cycloalkylene, phenylene lower alkyl or C.sub.4 -C.sub.7 -cycloalkylenyl lower alkyl, which comprises reacting a compound of the formula (I), as defined in claim 1, wehrein X is --NH.sub.2, with a maleinimide compound having the formula (III) ##STR43## wherein R.sup.2 is as hereinabove described.

13. The process for preparing a cytorhodin S derivative of the formula (I) as defined in claim 1, wherein X is a group of the formula ##STR44## wherein R.sup.2 and R.sup.4 are each independently lower alkylene, phenylene, C.sub.4 -C.sub.7 -cycloalkylene, phenylene lower alkyl or C.sub.4 -C.sub.7 -cycloalkylenyl lower alkyl, IgG represents an immunoglobulin moiety and n represents an integer of 1-15, which comprises reacting a compound of the formula (I) as defined in claim 1, wherein X is a group of the formula ##STR45## wherein R.sup.2 is as hereinbefore described, with a thiolated immunoglobulin having the formula (IV) ##STR46## wherein R.sup.4, IgG and n are as hereinbefore described.

14. The process for preparing a cytorhodin S derivative of the formula (I) as defined in claim 1, wherein X is a group of the formula ##STR47## wherein IgG represent an immunoglobulin moiety and n represents an integer of 1-15, which comprises reacting a compound of the formula (I) as defined in claim 1, wherein X is the group --NH--(CH.sub.2).sub.2 --SH, with a maleinimidated immunoglobulin having the formula (IV) ##STR48## wherein IgG and n are as hereinbefore described.

15. The process for preparing a cytorhodin S derivative of the formula (I) as defined in claim 1, wherein X is ##STR49## wherein R.sup.1 is unsubstituted C.sub.1 -C.sub.5 -alkylene or C.sub.1 -C.sub.5 -alkylene which is substituted with NH.sub.2 or SH, and wherein IgG represents an immunoglobulin moiety and n represents an integer from 1-15, which comprises reacting a compound of the formula (I) as defined in claim 1, wherein X is NH--R.sup.1 -COOH and R.sup.1 is as hereinbefore described, with an immunoglobulin having the formula (VI)

NH.sub.2 --(IgG).sub.1/n (VI)

wherein IgG and n are as hereinbefore described.